Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`anunttt
`(Use as many sheets as necessary)
`Examiner Name
`C. Rae
`
`ALTERNATIVE TO PTO/SB/08A/B
`(Based on PTO 03-08 version)
`
` US-5,703,117-A
`
`
` 12-30-1997 Mayhewetal.
`
`Attorney Docket Number
`
`|638772000109
`
`U.S. PATENT DOCUMENTS
`
`Zenoni et al. ©)NO}Or)|Go|Poy
`
`Pages, Columns, Lines, Where
`Name of Patentee or
`Examiner
`Publication Date
`Document Number
`Relevant Passages or Relevant
`29
`Initials*
`Applicant of Cited Document
`Number-Kind Code?(ifknown)|MM-DD-YYYY
`Figures Appear
`10-23-2003
`US-2003/0199425-A1
`Desaiet al.
`
`US-2005/0004002-A1 Desaiet al.
`01-06-2005
`US-2006/0083782-A1 04-20-2006 Desaiet al.
`US-2006/0121119-A1 06-08-2006 Zenoni et al.
`US-2006/0257326-A1 11-16-2006 Desaiet al.
`11-23-2006
`US-2006/0263434-A1
`Desaiet al.
`01-25-2007
`US-2007/0020337-A1
`US-2007/0082838-A1 04-12-2007 De et al.
`US-2007/0087022-A1 04-19-2007 Desaiet al.
`US-2007/0092563-A1 04-26-2007 Desaiet al.
`US-2007/0116774-A1 05-24-2007 Desaiet al.
`05-24-2007
`US-2007/0117133-A1
`Trieu et al.
`05-24-2007
`US-2007/0117744-A1
`Desaiet al.
`
`US-2007/01 17862-A1 Desaiet al.
`05-24-2007
`US-2007/01 17863-A1 05-24-2007 Desaiet al.
`US-2007/0128290-A1 06-07-2007 Desaiet al.
`US-2007/0129448-A1 06-07-2007 Desaiet al.
`07-19-2007
`US-2007/0166388-A1
`Desaiet al.
`
`08-23-2007
`US-2007/0196361-A1
`Soon-Shiong et al.
`08-13-1985
`Sears
`US-4,534,899
`
`10-22-1991
`US-5,059,699
`Kingston et al.
`11-08-1994 Desaiet al.
`US-5,362,478-A
`
`11-08-1994 Mongelli
`US-5,362,831-A
`03-21-1995
`Liversidge et al.
`US-5,399,363-A
`05-16-1995
`Straubingeret al.
`US-5,415,869-A
`Rahmanetal.
`06-13-1995
`US-5,424,073-A
`08-08-1995
`Desaiet al.
`US-5,439,686-A
`Grinstaff et al.
`03-12-1996
`US-5,498,421-A
`04-09-1996
`Grinstaff et al.
`US-5,505,932-A
`Grinstaff et al.
`04-16-1996
`US-5,508,021-A
`04-30-1996
`Grinstaff et al.
`US-5,512,268-A
`10-01-1996
`Soon-Shiong et al.
`US-5,560,933-A
`Kohn etal.
`10-15-1996
`US-5,565,478-A
`
`10-22-1996 Szoka,Jr.
`US-5,567,434-A
`04-01-1997 Kinsella et al.
`US-5,616,608-A
`05-06-1997
`Brem et al.
`US-5,626,862-A
`Eibl et al.
`05-06-1997
`US-5,626,867-A
`06-03-1997
`Grinstaff et al.
`US-5,635,207-A
`06-17-1997
`Grinstaff et al.
`US-5,639,473-A
`Rahmanetal.
`07-15-1997
`US-5,648,090-A
`07-22-1997 Grinstaff et al.
`US-5,650,156-A
`07-29-1997 Brem etal.
`US-5,651 ,986-A
`09-09-1997
`Grinstaff et al.
`US-5,665,382-A
`Grinstaff et al.
`09-09-1997
`US-5,665,383-A
`09-23-1997
`Durret al.
`US-5,670,536-A
`11-04-1997
`Boni et al.
`US-5,683,715-A
`
`Abraxis EX2004
`Actavis LLC v. Abraxis Bioscience, LLC
`IPR2017-01100
`padeRE FERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`/CR/
`
`

`

`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`ALTERNATIVE TO PTO/SB/08A/B
`(Based on PTO 03-08 version)
`
`Desaiet al.
`
`
`
`
`
`(Use as many sheets as necessary)
`Examiner Name
`C. Rae
`
`Attorney Docket Number
`
`|638772000109
`
`02-10-1998
`Hunteret al.
`US-5,716,981-A
`Wrasidlo
`03-24-1998
`US-5,731,334-A
`03-31-1998 Kunz et al.
`US-5,733,925-A
`05-26-1998 Gill
`US-5,756,537-A
`06-16-1998
`Spenleuhaueret al.
`US-5,766,635-A
`Shashoua etal.
`09-22-1998
`US-5,795,909-A
`09-22-1998
`Kunz et al.
`US-5,811,447-A
`03-23-1999
`Hunteret al.
`US-5,886,026-A
`Desaiet al.
`06-29-1999
`US-5,916,596-A
`07-27-1999 Davis et al.
`US-5,928,669-A
`08-31-1999 Yen
`US-5,945,033-A
`11-02-1999
`Li et al.
`US-5,977,163-A
`Kunz et al.
`11-09-1999
`US-5,981 ,568-A
`11-30-1999
`Hunteret al.
`US-5,994,341-A
`
`12-07-1999
`US-5,997,904-A
`Magdassi etal.
`
`04-18-2000 Mayhewetal.
`US-6,051,600-A
`05-23-2000 Hausheeretal.
`US-6,066,668-A
`06-13-2000 Kunz et al.
`US-6,074,659-A
`08-01-2000
`Desaiet al.
`US-6,096,331-A
`Ali et al.
`08-22-2000
`US-6,107,332-A
`09-19-2000
`Spenlehauer et al.
`US-6,120,805-A
`
`11-07-2000
`US-6,143,276-A
`Unger
`11-14-2000 Rahman
`US-6,146,659-A
`
`01-30-2001 Zhong
`US-6,179,817-B1
`03-06-2001
`Zhong
`US-6,197,051-B1
`03-06-2001
`Westesenetal.
`US-6,197,349-B1
`Kunz
`07-31-2001
`US-6,268,390-B1
`10-23-2001
`Kunz et al.
`US-6,306,421-B1
`Kim et al.
`11-27-2001
`US-6,322,805-B1
`08-27-2002 Li et al.
`US-6,441 ,025-B2
`09-24-2002 Lambert et al.
`US-6,458,373-B1
`12-31-2002
`Perkins et al.
`US-6,500,461 B2
`01-14-2003
`Desaiet al.
`US-6,506,405-B1
`
`03-04-2003
`US-6,528,067-B1
`Magdassi etal.
`03-25-2003
`Desaiet al.
`US-6,537,579-B1
`
`05-20-2003
`US-6,565,842-B1
`Sojomihardjo et al.
`11-25-2003
`Falciani
`US-6,652,884-B2
`
`06-01-2004
`US-6,743,826-B1
`Hegeduset al.
`06-15-2004
`Desaiet al.
`US-6,749,868-B1
`06-22-2004
`US-6,753,006-B1
`
`US-6,759,431-B2 07-06-2004|Hunteret al.
`|US-7,238,369-B2
`89.
`07-03-2007 |McDonald etal.
`
`90. 02-19-2008 |Trieu et al. |US-7,332,568-B2
`
`
`padREFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/CR/
`
`

`

`ALTERNATIVE TO PTO/SB/08A/B
`(Based on PTO 03-08 version)
`
`Substitute for form 1449/PTO
`
`complete it Known
`
`INFORMATION DISCLOSURE
`STATEMENTBY APPLICANT
`
`|fiss2"e [September 12, 2006
`Neil P. DESAI
`
`
`
`(Use as many sheets as necessary) C. Rae Examiner Name
`Attorney Docket Number
`
`
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner|Cte,|Farin Patent Document Name oPateniceor|yaiceuttes,vie
`
`
`
`
`
`Initials* Country Code®-Number*-Kind Code’®(if known)|MM-DD-YYYYNo.' Applicant of Cited Document OrRelevant Figures Appear| T®
`
`
`
`.
`Translation of
`91.
`|CN-1148957-A
`05-07-1997 |Zhang Hairu
`Abstract Only
`
`
`
`92. 12-09-1993|Clover Consolidated Limited_|WO-93/24476-A1 [|
`
`
`
`93.|WO-94/18954-A1 09-01-1994|Clover Consolidated Limited [|
`94.
`|WO-95/03036-A1
`02-02-1995 nngiogenesis Technologies,
`
`
`
`95.|WO-96/02247-A1 02-01-1996|Hemagen PFC
`96. 12-19-1996|VivoRx Pharmaceuticals, Inc.|WO-96/40091-A1
`
`
`
`97. 12-19-1996|VivoRx Pharmaceuticals, Inc.|WO-96/40829-A1
`
`98.
`|WO-97/10849-A1
`03-27-1997 |Sam Yang Co., Ltd.
`99. 04-09-1998|VivoRx Pharmaceuticals, Inc.|WO-98/14174-A1, C1 [|
`
`
`
`
`100.|WO-99/13914-A1 03-25-1999|Human Rt.
`
`Examiner
`Signature
`
`Date
`Considered
`
`*EXAMINER: Initial if information considered, whether ornotcitation is in conformance with MPEP 609. Drawline through citation if not in conformance and not
`considered.
`Include copy of this form with next communication to applicant.
`' Applicant's unique citation designation number (optional). *See Kinds Codes of
`USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
`° Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). “For
`Japanesepatent documents,the indication of the yearof the reign of the Emperor must precedethe serial numberof the patent document. °Kind of document by
`the appropriate symbols as indicated on the document under WIPO Standard ST.
`16 if possible.
`* Applicant is to place a check mark hereif English language
`Translation is attached.
`
`NON PATENT LITERATURE DOCUMENTS
`
`Examiner)
`Initials
`
`|638772000109
`
`
`
`
`
`
`
`
`Include nameof the author (in CAPITAL LETTERS), title of the article (when appropriate), title of
`Cite
`the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s}, volume-issue
`T
`No."
`number(s),
`publisher, city and/or country where published.
`101
`BARTOLI, M.H.et al. (April-June 1990). “In Vitro and In Vivo Antitumoral Activity of Free, and |
`*_|Encapsulated Taxol,” Journal of Microencapsulation 7(2):191-197.
`102.
`DESAI, N.P. et al. (April 1994). "Controlled and Targeted Drug Delivery With Biocompatible
`Protein Shell Microspheres," The 20th Annual Meeting of the Society for Biomaterials, Boston,
`
`MA, April 5-9, 1994, one page.
`DESAI, N.P. et al. (October - November 1994). "Intravenous Targeted Delivery of Chemo-
`103.
`therapeutic Agents in Protein Microspheres," X/V International Cancer Progress, New Delhi,
`
`India, October 30 - November 5, 1994, one page.
`DESAI, N.P. et al. (March 1995). “In Vivo Drug Delivery With Biocompatible Protein Shell
`Microspheres,” The 21% Annual Meeting of the Society for Biomaterials, San Francisco, CA,
`
`March 18-22, 1995, one page.
`|DESAI, N.P. et al. (August 1995). "Protein Microcapsules as Drug Delivery Vehicles," 26th
`105.
`
`Annual Meeting of the Fine Particle Society, Chicago, IL, August 22-25, 1995, one page.
`DESAI, N.P. et al. (April - May 1997). “Protein-Stabilized Nanoparticles as Drug Delivery
`Vehicles,” Transactions: 23Annual Meeting of the Society for Biomaterials, New Orleans, LA,
`April 30 - May 4, 1997, 20:172.
`|DESAI, N.P. et al. (April 1998). "Protein Based Nanoparticle Delivery Systems,” 28th Annual
`Meeting of the Fine Particle Society, Dallas, TX, April 1-3, 1998, one page.
`
`104.
`
`106.
`
`107.
`
`
`
`padREFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/CR/
`
`

`

`Substitute for form 1449/PTO
`
`complete it Known
`
`ALTERNATIVE TO PTO/SB/08A/B
`(Based on PTO 03-08 version)
`
`|fiss2"e [September 12, 2006
`INFORMATION DISCLOSURE
`Neil P. DESAI
`STATEMENTBY APPLICANT
`ame—————*i
`(Use as many sheets as necessary)
`Examiner Name
`C. Rae
`
`Attorney Docket Number
`
`|638772000109
`
`
`
`
`DOSIO, F. et al. (1997). “Preparation, Characterization and Properties In Vitro and In Vivo of a
`Paclitaxel-Albumin Conjugate,” J. Cont. Rel. 47:293-204.
`GRINSTAFF, M.W. et al. (March 1994). “Intravenous Targeted Delivery of Taxol in Protein
`109.
`|Microspheres,” Abstracts of Papers 207" National Meeting of the American Chemical Society,
`
`1994, San Diego, CA, March 13-17, 1994, 207(1-2), Abstract No. 91, one page.
`
`LEYLAND-JONES, B.
`(February 1993). “Targeted Drug Delivery,” Seminars in Oncology
`20(1):12-17.
`MATHEW, A.E. et al. (1992). “Synthesis and Evaluation of Some Water-Soluble Prodrugs and
`Derivatives of Taxol with Antitumor Activity,” J. Med. Chem. 35(1):145-151.
`
`108.
`
`110.
`
`111.
`
` attached.)
`
`P|tt
`120.
`
`
`
`
`MERISKO-LIVERSIDGE, E. (1996). “Formulation and Antitumor Activity Evaluation of
`|Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs,” Pharmaceutical Research
`13(2):272-278.
`
`112.
`
`113.
`114.
`
`118.
`
`RIONDEL,J. et al. (January - February 1992). “Effects of Free and Liposome-Encapsulated
`Taxol on Two Brain Tumors Xenografted into Nude Mice,” In Vivo 6(1):23-27.
`Non-Final Office Action mailed on June 22, 2007, for U.S. Application No. 11/544,737,filed on
`October 5, 2006, 9 pages.
`Non-Final Office Action mailed on June 22, 2007, for U.S. Application No. 11/544,794,filed on
`115.
`
`October 5, 2006, 9 pages.
`Non-Final Office Action mailed on June 14, 2007, for U.S. Application No. 11/544,523, filed on
`116.
`October 5, 2006, 8 pages.
`Non-Final Office Action mailed on June 22, 2007, for U.S. Application No. 11/544,781, filed on
`117.
`October 5, 2006, 9 pages.
`|Non-Final Office Action mailed on June 22, 2007, for U.S. Application No. 11/635,253, filed on
`December5, 2006, 9 pages.
`|Non-Final Office Action mailed on June 22, 2007, for U.S. Application No. 11/635,252, filed on
`119.
`
`December5, 2006, 9 pages.
`
`U.S. Patent Application No. 09/446, 783, filed on May 16, 2000, for Desai et al. (Copy not
`
`121.
`
`|U.S. Patent Application No. 09/937,840, filed on January 28, 2002, for Desai et al. (Copy not
`attached.)
`122
`U.S. Patent Application No. 11/553,339,filed on October 26, 2006, for Desai et al. (Copy not
`
`‘|
`attached.)
`123.
`|U.S. Patent Application No. 11/833,179, filed on August 2, 2007, for Desai et al. (Copy not
`attached.)
`
`124.
`
`125.
`
`126.
`
`127.
`
`128.
`
`|U.S. Patent Application No. 11/833,188, filed on August 2, 2007, for Desai et al. (Copy not
`attached.)
`
`|U.S. Patent Application No. 11/880,218, filed on July 19, 2007, for Desai et al. (Copy not
`attached.)
`
`|U.S. Patent Application No. 11/880,314, filed on July 20, 2007, for Desai et al.
`attached.)
`
`(Copy not
`
`|U.S. Patent Application No. 11/890,006, filed on August 3, 2007, for Desai et al.
`attached.)
`
`|U.S. Patent Application No. 11/890,041, filed on August 3, 2007, for Desai et al.
`attached.)
`
`(Copy not
`
`(Copy not
`
`(Copy not
`|U.S. Patent Application No. 11/890,197, filed on August 3, 2007, for Desai et al.
`129.
`attached.)
`
`padREFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/CR/
`
`

`

`Substitute for form 1449/PTO
`
`complete it Known
`
`ALTERNATIVE TO PTO/SB/08A/B
`(Based on PTO 03-08 version)
`
`|fiss2"e [September 12, 2006
`INFORMATION DISCLOSURE
`Neil P. DESAI
`STATEMENTBY APPLICANT
`ame—————*i
`(Use as many sheets as necessary)
`Examiner Name
`C. Rae
`
`Attorney Docket Number
`
`|638772000109
`
`130.
`
`|U.S. Patent Application No. 11/890,599, filed on August 6, 2007, for Desai et al.
`attached.)
`
`(Copy not
`
`131.
`|U.S. Patent Application No. 11/890,603, filed on August 6, 2007, for Desai et al. (Copy not
`
`attached.)
`
`
`
`132.
`
`U.S. Patent Application No. 11/890,6339, filed on August 6, 2007, for Desai et al.
`attached.)
`
`(Copy not
`
`133.
`|U.S. Patent Application No. 11/890,648, filed on August 6, 2007, for Desai et al.
`(Copy not
`
`attached.)
`
`134.
`
`|U.S. Patent Application No. 11/890,819, filed on August 7, 2007, for Desai et al.
`attached.)
`
`(Copy not
`
`135.
`|U.S. Patent Application No. 11/897,724, filed on August 31, 2007, for Desai et al.
`(Copy not
`
`attached.)
`
`
`
`
`
`
`
`(Copy not
`
`136.
`
`U.S. Patent Application No. 12/051,782, filed on March 19, 2008, for Desai et al.
`attached.)
`American BioScience, Inc. v. Baker Norton Pharmaceuticals, Inc. et al., Case No. CV 00-
`“109589 (MRP), before United States District Court for the Central District of California, 2002
`U.S. Dist. Lexis 512, January 10, 2002, four pages.
`
`137
`
` Charlesworth Rae/
`
`Considered
`
`08/14/2008
`
`Signature
`
`*EXAMINER: Initialif reference considered, whetheror not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not
`considered.
`Include copy of this form with next communicationto applicant.
`
`‘Applicant's unique citation designation number(optional). Applicantis to place a check mark hereif English language Translation is attached.
`
`padREFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/CR/
`
`